These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38153233)

  • 1. Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer.
    Xu H; Chen S; Li J; Weng S; Ren Y; Zhang Y; Wang L; Liu L; Guo C; Xing Z; Luo P; Cheng Q; Han X; Liu Z
    J Proteome Res; 2024 Feb; 23(2):760-774. PubMed ID: 38153233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEIS2 promotes cell migration and invasion in colorectal cancer.
    Wan Z; Chai R; Yuan H; Chen B; Dong Q; Zheng B; Mou X; Pan W; Tu Y; Yang Q; Tu S; Hu X
    Oncol Rep; 2019 Jul; 42(1):213-223. PubMed ID: 31115559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery.
    Huang M; He J; Lai W; Liu L; Xu H; Zeng Y; Lan Q; Lin X; Chu Z
    BMC Gastroenterol; 2022 Feb; 22(1):87. PubMed ID: 35227194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
    To KK; Tong CW; Wu M; Cho WC
    World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
    Brunac AC; Fourquet J; Perot G; Jaffrelot M; Meilleroux J; Danjoux M; Filleron T; Nicolaï V; Guimbaud R; Icher S; Farés N; Selves J; Chibon F
    Mod Pathol; 2022 Dec; 35(12):2002-2010. PubMed ID: 36202996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
    Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
    Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Prognostic Significance of HOXC9 Expression in Patients with Colorectal Cancer.
    Hu M; Ou-Yang W; Jing D; Chen R
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between TBL1XR1 and recurrence of colorectal cancer.
    Liu H; Xu Y; Zhang Q; Li K; Wang D; Li S; Ning S; Yang H; Shi W; Liu Z; Chen Y
    Sci Rep; 2017 Mar; 7():44275. PubMed ID: 28295012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.
    Okugawa Y; Toiyama Y; Toden S; Mitoma H; Nagasaka T; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Gut; 2017 Jan; 66(1):107-117. PubMed ID: 26475630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.
    Wang W; Kandimalla R; Huang H; Zhu L; Li Y; Gao F; Goel A; Wang X
    Semin Cancer Biol; 2019 Apr; 55():37-52. PubMed ID: 29775690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
    Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
    Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis.
    Lin H; Xia L; Lian J; Chen Y; Zhang Y; Zhuang Z; Cai H; You J; Guan G
    J Transl Med; 2021 Dec; 19(1):497. PubMed ID: 34876143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.